Key Takeaways for Cooper Companies Stock as of September 2026
- Guidance Shock: Cooper Companies stock plunged 15% on Thursday, September 10, after the company cut FY2026 EPS guidance to $4.51-$4.55 and its board walked away from selling CooperSurgical, ending months of takeout speculation.
- Street Split: Cooper Companies stock now carries 16 analyst ratings on TIKR, split 3 buys, 2 outperforms, and 11 holds, with a mean target of $80, 47% above Thursday’s close.
- Model Upside: TIKR’s mid-case model values Cooper Companies stock at $73 by October 2030, a 34% total return and 7% annualized from here.
- Conviction Erosion: Buy ratings on the stock fell from 8 to 3 over the past year.
Cooper Companies stock just fell 15% while the Street’s target barely moved. Pull the ratings history and valuation model yourself: Analyze COO stock on TIKR for free →
Why Cooper Companies Stock Crashed 15% on a Guidance Cut and Scrapped Sale
Cooper Companies (COO) stock crashed 15% on Thursday, September 10, closing at $54 after the medical device maker cut its full year profit forecast and its board walked away from selling CooperSurgical.
The numbers behind the move came out Wednesday evening, when Cooper posted third quarter revenue of $1.07 billion, short of the $1.10 billion analysts expected. Adjusted earnings of $1.15 a share beat the $1.12 consensus, an eleventh straight quarter of topping estimates. But the top line miss set up what followed.
Management cut its annual outlook hard: full year revenue moved to $4.23 billion to $4.25 billion, down from a prior $4.29 billion to $4.32 billion and below the $4.31 billion Street estimate. Adjusted EPS guidance fell to $4.51 to $4.55, versus $4.58 to $4.66 before and a $4.63 consensus. Fourth quarter guidance landed even further from expectations, at $1.057 billion to $1.08 billion in revenue and EPS of $1.05 to $1.09, compared with a $1.19 consensus.
The cut traces to one specific decision inside CooperVision, the contact lens unit that makes up most of Cooper’s revenue. Management chose to pull inventory out of the U.S. distribution channel faster than usual, a move that shows up immediately as lower shipments even though nothing changed at the register. Chief Executive Albert White was direct about it on the earnings call. “The entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory,” he told analysts. “That’s it.” He pointed to consumption growth still running at a mid single digit pace in the U.S., separating what patients are buying from what distributors are holding.
The second piece of Thursday’s drop came from a decision Cooper had been building toward for months. The board completed its strategic review of CooperSurgical, the fertility and medical device unit it had explored selling, and chose to keep it. Executives said late offers undervalued the business, pointing to a newly approved competing non-hormonal IUD and lingering noise from a fertility litigation settlement as factors that temporarily depressed what buyers were willing to pay. Investors who had priced in a sale premium lost it overnight.
Not everything in the release was bad. Cooper booked a $307 million discrete tax benefit after resolving an examination by the UK’s tax authority, HMRC, pushed free cash flow to a record $273 million for the quarter, and raised its buyback authorization to $3 billion from $2 billion. CooperSurgical itself grew revenue 3% organically, with the fertility business up 5%. None of that offset the headline miss, but it does separate a temporary inventory problem from a broken business.
The move repriced a stock that management insists is dealing with a channel problem, not a demand problem, and that distinction is what the rest of this article has to test.
Cooper’s channel cleanup is supposed to end this quarter. See how CooperVision’s regional trends have moved on TIKR: Track COO stock on TIKR for free →
Cooper Companies Stock Trades 47% Below a Cautious Street’s Mean Target
TIKR tracks 16 analysts on Cooper Companies stock, and the mix has turned cautious: 3 buys, 2 outperforms, and 11 holds. The mean target sits at $80, 47% above Thursday’s $54 close, the widest gap this table has shown in the past year.
That gap did not open gradually. On July 31, the mean target stood at $81 against a $72 close, just 12% of implied upside, the tightest reading of the past year. Cooper Companies stock has since fallen 25% on the guidance cut and the scrapped CooperSurgical sale, while the mean target moved just 2%, down to $80.
Ratings tell the same story from a different angle: buy calls have dropped from 8 a year ago to 3 now, with holds swelling from 6 to 11 over the same stretch. Analysts are cutting conviction faster than they are cutting numbers, and that gap is what the TIKR model has to price next.
TIKR Values Cooper Companies Stock at $73, Pricing In a Destock Recovery
TIKR’s mid-case model values Cooper Companies stock at $73 by October 2030, implying a 34% total return from the current $54 price, or 7% annualized over roughly four years.
That pace lands closer to what investors expect from a steady healthcare compounder than from a broken franchise, positioning Cooper Companies stock as a recovery play rather than a value trap.
Cooper Companies stock trades at 11.92 times forward earnings, the lowest multiple of the past two years and 43% below its 20.97x mean, so the model’s 34% return leans on a multiple that has already compressed rather than a bet on paying up for the same earnings.
The target is reachable because the entire guidance cut traces to inventory Cooper is removing on purpose, not to a shift in patient demand, and the Street’s $80 mean target sitting 47% above the price shows analysts have not abandoned the long term story either. Management says the fourth quarter is when the channel clears, positioning 2027 growth to reset closer to the mid single digit consumption trend it described on the call.
Should You Invest in The Cooper Companies, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up The Cooper Companies, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track The Cooper Companies, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze COO stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
